'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States

K Dubé, 2014, Framing expectations in early HIV cure research, Trends in Microbiology, 22, 547, 10.1016/j.tim.2014.08.003

N Eyal, 2016, The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction, Journal of medical ethics, 1

K Dubé, 2017, Willingness to participate in HIV cure research: survey results from 400 people living with HIV in the United States, Journal of Virus Eradication, 3, 40, 10.1016/S2055-6640(20)30295-8

FDA (2013) Backgrounder for FDA’s HIV Patient-Focused Drug Development and HIV Cure Research Public Meeting. Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM354549.pdf" xlink:type="simple">http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM354549.pdf</ext-link>.

NM Archin, 2014, Emerging strategies to deplete the HIV reservoir, Current Opinion in Infectious Diseases, 27, 29, 10.1097/QCO.0000000000000026

DM Margolis, 2013, Combined approaches for HIV cure, Current Opinion in HIV and AIDS, 8, 230, 10.1097/COH.0b013e32835ef089

TAG (2016) Research Toward a Cure Trials. Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.treatmentactiongroup.org/cure/trials" xlink:type="simple">http://www.treatmentactiongroup.org/cure/trials</ext-link>.

Y Lo, 2015, Stakeholder engagement in HIV cure research: lessons learned from other HIV interventions and the way forward, AIDS Patient Care and STDs, 29, 1

UCLA Center for Health Policy Research (2016) Key Informant Interviews. Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://healthpolicy.ucla.edu/programs/health-data/data-resources/Pages/Key-Informant-Interviews.aspx" xlink:type="simple">http://healthpolicy.ucla.edu/programs/health-data/data-resources/Pages/Key-Informant-Interviews.aspx</ext-link>.

J Cresswell, 2013, Research Design: Qualitative, Quantitative, and Mixed Methods Approaches, 142

J DeCuir-Gunby, 2003, Techniques to Identify Themes, Field Methods, 15, 85, 10.1177/1525822X02239569

R Krueger, 2009, Focus Groups: A Practical Guide for Applied Research

JM Prins, 1999, Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy, AIDS (London, England), 13, 2405, 10.1097/00002030-199912030-00012

CE Chu, 2015, Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China, AIDS Research and Human Retroviruses, 31, 78, 10.1089/aid.2014.0200

Ma Q, Wu F, Henderson G, Rennie S, Rich ZC, Cheng Y, et al. (2016) “I can coexist with HIV”: a qualitative study of perceptions of HIV cure among people living with HIV in Guangzhou, China: 170–174.

K Moodley, 2015, HIV cure research in South Africa: a preliminary exploration of stakeholder perspectives, AIDS Care, 0121, 1

R Dresser, 2016, First-in-human HIV-remission studies: reducing and justifying risk, Journal of medical ethics, 1

N King, 2005, Consent forms and the therapeutic misconception: the example of gene transfer research, IRB: Ethics and Human Research, 27, 1, 10.2307/3563865

GE Henderson, 2006, Therapeutic misconception in early phase gene transfer trials, Social Science & Medicine (1982), 62, 239, 10.1016/j.socscimed.2005.05.022

FDA (2014) The Voice of the Patient. Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM389379.pdf" xlink:type="simple">http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM389379.pdf</ext-link>.

DHHS (n.d.) Code of Federal Regulations Title 45 Part 46 Protection of Human Subjects. Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hhs.gov/ohrp/newsroom/rfc/comstdofcare.html" xlink:type="simple">http://www.hhs.gov/ohrp/newsroom/rfc/comstdofcare.html</ext-link>.

A Rid, 2011, A framework for risk-benefit evaluations in biomedical research, Kennedy Institute of Ethics Journal, 21, 141, 10.1353/ken.2011.0007

Dubé K, Ramirez C, Handibode J, Taylor J, Skinner A, Greene SB, et al. (2015) Participation in HIV cure-related research: a scoping review of the proxy literature and implications for future research: 14–20.

NIH (2012) Organ Transplants Without Lifelong Drugs. Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nih.gov/news-events/nih-research-matters/organ-transplants-without-life-long-drugs" xlink:type="simple">https://www.nih.gov/news-events/nih-research-matters/organ-transplants-without-life-long-drugs</ext-link>.

J Hutchinson, 2015, Now or Never? The Case for Cell-Based Immunosuppression in Kidney Transplantation, Kidney International, 87, 1116, 10.1038/ki.2015.50

BDB Resnik, 2013, What is a “Reasonably Foreseeable Risk”? The SUPPORT Study Controversy, Journal of Clinical Research Best Practices, 9

CH Braddock, 2013, Supporting shared decision making when clinical evidence is low, Medical Care Research and Review, 70, 129S, 10.1177/1077558712460280

R Dressler, 2001, When science offers salvation. Patient advocacy and research ethics

JA Fisher, 2007, “Ready-to-recruit” or “ready-to-consent” populations? Informed consent and the limits of subject autonomy, Qualitative Inquiry, 13, 875, 10.1177/1077800407304460

GE Henderson, 2015, The ethics of HIV “cure” research: what can we learn from consent forms?, AIDS Research and Human Retroviruses, 31, 56, 10.1089/aid.2014.0219

J Różyńska, 2015, On the alleged right to participate in high-risk research, Bioethics, 29, 451, 10.1111/bioe.12146

CT Deakin, 2013, Gene therapy researchers’ assessments of risks and perceptions of risk acceptability in clinical trials, Molecular Therapy, 21, 806, 10.1038/mt.2012.230

N Eyal, 2013, Challenges in clinical trial design for HIV-1 cure research, Lancet, 382, 1464, 10.1016/S0140-6736(13)62040-1

Gilbertson A (2016) Unanticipated participant benefits in HIV cure clinical research: a qualitative analysis. Towards an HIV Cure Symposium. Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.iasociety.org/HIV-programmes/Towards-an-HIV-Cure/Events/2016-Symposium/Day-1" xlink:type="simple">https://www.iasociety.org/HIV-programmes/Towards-an-HIV-Cure/Events/2016-Symposium/Day-1</ext-link>.

T Godskesen, 2013, Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation, Supportive Care in Cancer, 21, 3137, 10.1007/s00520-013-1891-7

B Lo, 2013, Ethical considerations in HIV cure research: points to consider, Current Opinion in HIV and AIDS, 8, 243, 10.1097/COH.0b013e32835ea1c5

H Peay, 2015, What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent, Journal of Virus Eradication, 1, 51, 10.1016/S2055-6640(20)31143-2

E Largent, 2016, For love and money: the need to rethink benefits in HIV cure studies, Journal of medical ethics, 1

L Balfour, 2010, Altruism motivates participation in a therapeutic HIV vaccine trial (CTN 173), AIDS Care, 22, 1403, 10.1080/09540121003693522

L Buchak, 2016, Why high-risk, non-expected-utility-maximising gambles can be rational and beneficial: the case of HIV cure studies, Journal of medical ethics, 1

GE Henderson, 2007, Clinical trials and medical care: defining the therapeutic misconception, PLoS Medicine, 4, e324, 10.1371/journal.pmed.0040324

CI Grossman, 2016, Towards multidisciplinary HIV-cure research: integrating social science with biomedical research, Trends in Microbiology, 24, 5, 10.1016/j.tim.2015.10.011

JD Tucker, 2014, Social and ethical implications of HIV cure research, AIDS (London, England), 28, 1247, 10.1097/QAD.0000000000000210